Keyword: Valneva

Here is some other vaccine news of note for the week.

While Valneva already markets two vaccines, the company is open to building its commercial business through small acquisitions, its CEO said.

Here is some other vaccine news of note for the week.

The FDA fast-tracked Valneva's shot against chikungunya, a disease with no approved vaccines.

Since GSK pulled LYMErix in 2002, there's been no FDA-approved Lyme shot, and Valneva's VLA15 is the only active clinical program.

A Zika vaccine candidate co-developed by Emergent BioSolutions and Valneva has turned up positive early-stage results.

Here is some other vaccine news of note for the week.

Here is some other vaccine news of note for the week.

Valneva is seeking a partner for a Lyme disease vaccine development effort it expects will cost $350 million.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.